real-time news and commentary for investors
Monday, Dec 17
2012, 4:10 PM
Medtronic (MDT) announces one-year results from its first randomized clinical trial...
Medtronic (MDT) announces one-year results from its first randomized clinical trial investigating renal denervation showing patients who initially received treatment with the Symplicity renal denervation system sustained a significant drop in blood pressure compared to baseline at 12 months, plus no device-related serious adverse events, no late vascular complications, and no significant decline in kidney function.